Menopause

Two neurokinin receptor antagonists are now available for vasomotor symptom (VMS)-related sleep disruption, with elinzanetant's (Lynkuet) NK1 and NK3 dual-receptor profile potentially offering more targeted sleep benefit than fezolinetant's (Veozah) NK3-selective mechanism—but effective management requires systematic screening for obstructive sleep apnea, restless leg syndrome, and primary insomnia before attributing sleep disruption to VMS alone

A study of 1206 women found that while many remain sexually active as they age, a higher number of menopausal symptoms was linked to decreased sexual satisfaction.

Contemporary OB/GYN will be on site in Washington, D.C. to cover the latest data out of the 75th Annual ACOG Clinical & Scientific Meeting.

The letter from the federal agency allows further phase 2 development for refisolone under an investigational new drug application.

ACOG now recommends a combination of transvaginal ultrasonography and endometrial tissue sampling for the initial evaluation of most patients presenting with postmenopausal bleeding.

According to ACOG, approximately 90% of patients diagnosed with endometrial cancer have postmenopausal bleeding. Read more on the College's updated recommendations below.

"These recommendations underscore the important and nuanced role of BMI in women’s health," write the authors.

In this video from the 2026 American College of Cardiology Annual Scientific Session & Expo, Amy Sarma, MD, details associations of cardiovascular disease and menopause.

Among a survey of over 800 providers, menopause care was the top area for expected greatest improvement over the next 5 years.

Data suggest that thermal biomodulation via radiofrequency improves vaginal lubrication and reduces pain during intercourse for postmenopausal women.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Julia Ordway highlights a case where unregulated testosterone pellets led to a 2-year recovery period.

A prospective observational study found that age did not independently affect bone mineral density response to romosozumab in postmenopausal women.

"Ethical menopause care requires rebuilding trust through transparency, evidence, and shared decision-making," writes Barbara Levy, MD, FACOG, FACS.

The label changes to 6 menopausal HRTs "clarify risk considerations for these drugs," according to a statement from the FDA.

Women who experienced menopause before age 50 had higher rates of MASLD and adverse metabolic outcomes, according to reasearch published in Diabetes Metabolism Research and Reviews.

Take a quick look at everything you may have missed in January, from our latest video interviews to new clinical trial data to a FAQ on cervical cancer.

New national data show major declines in RA mortality among older women, alongside enduring racial and geographic inequities.

Menopause was associated with increased anxiety, depression, sleep problems and reductions in grey matter in key brain regions.

New data suggest that diabetes risk after menopause is driven by cardiometabolic factors rather than when or how menopause occurs.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

A study found no clear evidence that menopause hormone therapy increases or reduces dementia risk.

Check out the 5 biggest menopause stories of 2025, and review best practices.

Recent FDA approvals and emerging research highlight how neurokinin receptor antagonists are expanding nonhormonal options for managing vasomotor symptoms.